Nektar Therapeutics (Nasdaq: NKTR) reversed year ago losses of 37 cents per diluted share to post a stronger than expected profit of 25 cents per diluted share for the first quarter. The stock price soared $1.96 to close at $11.48.
Nektar Therapeutics swings to profit
May 01, 2015 at 19:30 PM EDT
